Related Experiment Videos
Update on the Kabi International Growth Study, April 1989
Insights
Recombinant human growth hormone (rhGH) effectively treats short stature in children. This study evaluated rhGH efficacy and safety in 987 children, finding it beneficial for growth hormone deficiency (GHD) and non-GHD conditions.
Area of Science:
- Pediatrics
- Endocrinology
- Biotechnology
Background:
- Short stature in children is a significant concern addressed by growth hormone therapy.
- Recombinant human growth hormone (rhGH) is a key therapeutic agent for various pediatric growth disorders.
Purpose of the Study:
- To prospectively evaluate the efficacy and safety of rhGH treatment.
- To analyze patient demographics and diagnostic categories for short stature.
Main Methods:
- Prospective evaluation of 987 children treated with rhGH up to April 1989.
- Categorization of patients into growth hormone deficiency (GHD) and non-GHD groups.
- Analysis of diagnoses, age at treatment onset, and height standard deviation scores (SDS).
Main Results:
- 84.7% of children had GHD, predominantly idiopathic (IGHD).
- Non-GHD group included idiopathic short stature and Turner's syndrome.
- Treatment onset varied by GHD type, with height SDS around -3.0 at initiation.
Conclusions:
- rhGH treatment is effective for children with various short stature conditions, including GHD and non-GHD.
- Understanding patient subgroups is crucial for optimizing rhGH therapy outcomes.
- Further research should explore long-term safety and efficacy across diverse pediatric populations.
Abstract:
The efficacy and safety of recombinant human growth hormone (rhGH) treatment is under prospective evaluation in children with various short stature conditions. Of the 987 children enrolled up to April 1989, 836 (84.7%) had classic growth hormone deficiency (GHD) and 151 (15.3%) non-GHD. There was a predominance of idiopathic growth hormone deficiency (IGHD), with a ratio of IGHD to secondary or organic GHD (OGHD) of 2.2:1. There were more boys than girls in both the IGHD and OGHD groups. Isolated GHD was more common than multiple pituitary hormone deficiency except in some of the groups with OGHD. About half of the OGHD patients had GHD secondary to treatment for CNS tumours. Idiopathic short stature and Turner's syndrome were the most common diagnoses in the non-GHD group. The median age at onset of treatment in IGHD was 8.2 years for boys and 8.6 years for girls. The corresponding figures for OGHD were 14.0 years and 12.2 years, respectively. The height SDS for chronological age at the start of treatment was -3.0 for IGHD and slightly less for children with OGHD. Approximately one-third of the children had already reached puberty at the start of hGH treatment.